AHF: Gilead's Greed Kills Promise of Lenacapavir for HIV Prevention
LOS ANGELES--(BUSINESS WIRE)--The U.S. Food and Drug Administration approved use of Gilead's HIV treatment medication, lenacapavir, for use to prevent HIV infection earlier today, an action which was followed by news that Gilead intends to price the HIV prevention medication at over $28,000 per patient, per year. AIDS Healthcare Foundation (AHF) President Michael Weinstein sharply criticized Gilead's outrageous pricing in the following statement:
'By pricing lenacapavir at over $28K per patient, per year, Gilead is sacrificing potential worldwide control and elimination of HIV on the altar of its bottom line.'
'What could be an extraordinary game changer for HIV prevention is being completely undermined by Gilead ' s greed. Charging $28,218 a year will drastically limit the availability of the drug. Gilead continues to feast on tens of billions of dollars, much of which is public funding for their HIV portfolio, at the expense of people living with or at risk of acquiring HIV. Gilead is sacrificing control of HIV on the altar of their bottom line.'
AIDS Healthcare Foundation (AHF), the world's largest HIV/AIDS healthcare organization, provides cutting-edge medicine and advocacy to more than 2.3 million individuals across 48 countries, including the U.S. and in Africa, Latin America/Caribbean, the Asia/Pacific Region, and Eastern Europe. In January 2025, AHF received the MLK, Jr. Social Justice Award, The King Center's highest recognition for an organization leading work in the social justice arena. To learn more about AHF, visit us online at AIDShealth.org, find us on Facebook, and follow us on Instagram, Twitter, and TikTok.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
4 hours ago
- UPI
NIH office to phase out HIV guidelines by next year
The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS patients in the United States is making major changes. File Photo by Annabelle Gordon/UPI | License Photo June 21 (UPI) -- The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS patients in the United States is making major changes. The NIH Office of AIDS Research or OAR told its employees this week it intends to phase out the guidelines by next June, the Washington Post reported, citing an internal staff email. According to the office, OAR "coordinates HIV/AIDS research across the National Institutes of Health and provides the largest public investment in HIV/AIDS research globally." "In the climate of budget decreases and revised priorities, OAR is beginning to explore options to transfer management of the guidelines to another agency within" the letter obtained by The Post reads. The OAR guidelines contain guidelines related to diagnosis and treatments of HIV and AIDS. There are currently more than 1 million people living with HIV in the United States. It was not immediately clear what the other agency referred to in the letter was or how such a move may affect the guideline, the Post reported. The news comes as President Donald Trump and Secretary of State Marco Rubio move to cut over $8 billion from the U.S. Agency for International Development, USAID and merge it into the State Department. State Department officials say the move comes with the expectation that other countries will increase their roles in delivering aid around the world. An April report published in the Lancet medical journal found around half a million children globally could die from AIDS by 2030 if the United States cuts its global relief funding. Earlier this week, the U.S. Food and Drug Administration approved use of the HIV drug lenacapavir, which is produced by California-based biopharma firm Gilead Sciences under the name Yeztugo. "Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic," Gilead Science Chairman and Chief Executive Officer Daniel O'Day said in a statement on the company's website
Washington Post
12 hours ago
- Washington Post
Administration to phase out NIH support of HIV clinical guidelines
The National Institutes of Health's support for federal guidelines that steer the treatment of more than a million HIV patients in the United States will be phased out by next June, according to the agency's Office of AIDS Research, a move that troubled some doctors and raised questions about whether the guidelines themselves will change. It is unclear whether Health and Human Services Secretary Robert F. Kennedy Jr. plans to bring the guidance in line with his own controversial views about an infectious disease that 30 years ago was the leading cause of death for people 25 to 44 years old. The Office of AIDS Research, which is part of the National Institutes of Health, informed members of the panels responsible for the guidelines in a letter that, 'in the climate of budget decreases and revised priorities, OAR is beginning to explore options to transfer management of the guidelines to another agency within' HHS. The guidelines, detailed recommendations on how to diagnose and treat medical conditions, can affect what tests, treatments and medications are covered by insurance companies and Medicare, said Aniruddha Hazra, associate professor of medicine at University of Chicago Medicine. The lack of clarity in the letter caused some in the medical community to worry that switching oversight of the guidelines to another branch of HHS could be a first step by the Trump administration toward more drastic changes in the government's treatment recommendations. 'From a practical standpoint, it's monumental,' Hazra said of the news about the guidelines, which he called the basis for much of the knowledge about HIV. 'The loss of this kind of federal guidance throws everything into the dark,' he said. Hazra described the guidelines as a dynamic document that changes at least once or twice a year as new studies and scientific evidence come to light. Guidelines for HIV are divided into a half-dozen categories, including sets for adults/adolescents, pediatric patients, pregnant women and HIV patients who are displaced by natural disasters. The webpage listing the guidelines now says they are 'being updated to comply with Executive Orders,' raising the question of whether sections dealing with care for transgender people with HIV may be changed or eliminated. The letter sent to panel members did not say specifically if or how the clinical practice guidelines might change, only that 'Together, we now have an opportunity to develop a proactive, careful transition plan for each Panel.' The letter noted that 'a special session on guidelines sustainability planning' has been scheduled for Thursday with panel leadership and the Office of AIDS Research Advisory Council. Officials at NIH referred questions to the Department of Health and Human Services, which did not respond to emails requesting clarification of the letter. Kennedy has long espoused controversial views about HIV, suggesting that contrary to widely held medical belief, the virus was not the cause of AIDS. In a video posted on Twitter in 2023, Kennedy tells an audience, 'A hundred percent of the people who died at first, the first thousand who had AIDS, were people who were addicted to [a class of drugs called] poppers. … They were people who were part of a gay lifestyle. They were burning the candle at both ends, and they were taking a lot of injectable drugs.' Under Kennedy, HHS has terminated hundreds of millions of dollars in HIV-related research grants. The department closed its Office of Infectious Diseases & HIV Policy that coordinated the federal response to the virus. At the same time, the Centers for Disease Control and Prevention lost staff in its HIV prevention division who conducted studies and surveillance, ran health campaigns and supported local prevention programs. 'These guidelines serve as a reference for the world in addition to caring for people in the U.S.,' said Theodore Ruel, chief of the Division of Pediatric Infectious Diseases and Global Health at UCSF Benioff Children's Hospital, and co-chair of one of the panels responsible for the guidelines. 'It is disappointing that such a key guideline about HIV for children in the USA will no longer be supported by the NIH,' said Ruel — whose panel examines antiretroviral therapy for the medical management of children living with HIV — stressing that he was not speaking for the other panelists. 'I am concerned that we are unlikely to find a new home that can maintain the same depth, quality, access and capacity for real-time updating.' He expressed faith that the panelists would push to find a home for the guidelines where they can continue to offer 'science-driven support' for doctors and patients. James M. Sosman, medical director for UW Health's HIV Care and Prevention Program, who has been caring for people with the disease for decades, said that having the guidelines under the auspices of the Office of AIDS Research made sense. 'Would I look to move that? I'm reluctant because it's like, 'Hey, if you've got a guy that's hitting home runs at third base, don't move them to first base,'' Sosman said. 'I mean if it's working out, why are you disrupting this for costs that don't seem that great.'
Washington Post
13 hours ago
- Washington Post
Here's what everyone should know about this new HIV prevention shot
A twice-a-year shot to prevent HIV has the potential to greatly reduce the spread of the virus in the United States and the rest of the world, but concerns about cost and accessibility remain, health care experts said. Yeztugo (generic name lenacapavir), made by Gilead Sciences, received approval from the Food and Drug Administration on Wednesday.
